Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 39,600 shares of the biopharmaceutical company's stock after selling 2,900 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Regeneron Pharmaceuticals were worth $25,116,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Pamalican Asset Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $4,915,000. Intact Investment Management Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $356,000. Rhenman & Partners Asset Management AB increased its position in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares in the last quarter. Fagan Associates Inc. increased its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after buying an additional 3,832 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after buying an additional 814,713 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.2%

NASDAQ REGN traded down $6.56 during midday trading on Monday, hitting $522.68. 1,324,804 shares of the company traded hands, compared to its average volume of 881,131. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company's 50-day simple moving average is $563.19 and its 200-day simple moving average is $648.52. The company has a market cap of $56.43 billion, a PE ratio of 13.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm posted $9.55 earnings per share. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on REGN shares. Royal Bank of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research note on Friday, May 30th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating for the company in a research note on Monday, June 2nd. Finally, UBS Group lowered their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $836.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.